Antitransforming Growth Factor-beta Antibody 1D11 Ameliorates Normal Tissue Damage Caused by High-dose Radiation
Overview
Affiliations
Purpose: The aim of this study was to determine whether a neutralizing transforming growth factor-beta (TGFbeta) antibody can prevent radiation (RT) induced lung injury.
Methods And Materials: Fractionated and sham right lung irradiation in Fischer 344 rats was delivered to assess the radioprotective effect of the antibodies. Animals were divided into the following groups: (1) control (sham RT, control antibody 13C4); (2) RT (800cGy x 5)+13C4); (3) RT + 0.1 mg/kg 1D11 anti-TGFbeta antibody; and (4) RT + 1 mg/kg 1D11 antibody. Antibodies were intraperitoneally administered immediately after the last fraction of RT. Animals were sacrificed at 6 and 26 weeks after irradiation. Lungs were assessed for histologic changes, activation of macrophages, expression/activation of TGFbeta and its signal transduction pathway.
Results: At 6 weeks post-RT, there was a significant reduction in macrophage accumulation (p = 0.041), alveolar wall thickness (p = 0.0003), and TGF-beta activation (p = 0.032) in animals receiving 1.0 mg/kg 1D11 vs. in the control group. However, at 6 weeks, the low dose of 1D11 antibody (0.1 mg/kg) failed to produce any significant changes. At 6 months post-RT, radioprotection is apparent for the group receiving 1.0 mg/kg 1D11, with activated macrophages (p = 0.037), alveolar wall thickness (p = 0.0002), TGFbeta activation (p = 0.002) and its signal transduction proteins (p < 0.05) compared with the control group.
Conclusions: Administration of a single dose of 1.0 mg/kg of the anti-TGFbeta antibody 1D11 resulted in decreased morphologic changes, inflammatory response, and reduced expression and activation of TGFbeta 6 weeks and 6 months after 40 Gy to the right hemithorax. Targeting the TGFbeta pathway may be a useful strategy to prevent radiation-induced lung injury.
Liu H, Yang C, Gao Y, Zhang X, Wang M, Yu X Bioeng Transl Med. 2023; 8(5):e10555.
PMID: 37693057 PMC: 10486326. DOI: 10.1002/btm2.10555.
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations.
Karapetyan L, Iheagwara U, Olson A, Chmura S, Skinner H, Luke J J Natl Cancer Inst. 2023; 115(11):1278-1293.
PMID: 37348864 PMC: 10637035. DOI: 10.1093/jnci/djad118.
Rodrigues Ferreira R, de Souza E, Vilar-Pereira G, Degrave W, Abreu R, Meuser-Batista M Front Cell Infect Microbiol. 2022; 12:1017040.
PMID: 36530434 PMC: 9748701. DOI: 10.3389/fcimb.2022.1017040.
Kadam A, Kandasamy K, Buss T, Cederstrom B, Yang C, Narayanapillai S PLoS One. 2022; 17(11):e0276462.
PMID: 36413536 PMC: 9681080. DOI: 10.1371/journal.pone.0276462.
Liquid biopsy in NSCLC: a new challenge in radiation therapy.
Perillo A, Olufemi M, De Robbio J, Mancuso R, Roscigno A, Tirozzi M Explor Target Antitumor Ther. 2022; 2(2):156-173.
PMID: 36046142 PMC: 9400754. DOI: 10.37349/etat.2021.00038.